Back HCV Treatment

HCV Treatment

EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

Read more:

EASL 2016: International Liver Congress Underway this Week in Barcelona

The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.

alt

Read more:

CROI 2016: Advances in Hepatitis C Research [VIDEO]

Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.

alt

 

Read more:

CROI 2016: Hepatitis C [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

 

Read more:

CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C

Direct-acting antiviral therapy for hepatitis C delivered by non-specialists such as primary care physicians and nurse practitioners is safe and effective -- even for the most difficult-to-treat patients -- and could potentially help increase the number of people receiving treatment, according to findings from the ASCEND study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.

alt

Read more: